PODD241220P260000
- 3.22
- +0.67+26.27%
Insulet Newsroom
CCORF Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $269
Insulet's Strategic Advancements and Market Positioning Drive Buy Rating
Morgan Stanley Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $317
Insulet Is Maintained at Overweight by Morgan Stanley
Barclays Adjusts Price Target on Insulet to $234 From $220, Maintains Equalweight Rating
Barclays Sticks to Its Hold Rating for Insulet (PODD)
Analysts Are Bullish on These Healthcare Stocks: Insulet (PODD), Genfit (GNFTF)
A Quick Look at Today's Ratings for Insulet(PODD.US), With a Forecast Between $245 to $300
Wells Fargo Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $290
TD Cowen Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $264
Insulet's Strong Market Performance and Growth Justify Buy Rating
Insulet Analyst Ratings
Bernstein Initiates Insulet(PODD.US) With Buy Rating, Announces Target Price $300
Insulet Is Maintained at Buy by BTIG
Insulet Analyst Ratings
Raymond James Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $260
BTIG Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $260
Baird Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $280
Insulet Analyst Ratings
Citi Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $275